COSMO Pharmaceuticals SA - Asset Resilience Ratio
COSMO Pharmaceuticals SA (0RGI) has an Asset Resilience Ratio of 0.19% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does COSMO Pharmaceuticals SA carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how COSMO Pharmaceuticals SA's Asset Resilience Ratio has changed over time. See COSMO Pharmaceuticals SA book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down COSMO Pharmaceuticals SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of COSMO Pharmaceuticals SA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | £0.00 | 0% |
| Short-term Investments | £1.18 Million | 0.19% |
| Total Liquid Assets | £1.18 Million | 0.19% |
Asset Resilience Insights
- Limited Liquidity: COSMO Pharmaceuticals SA maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
COSMO Pharmaceuticals SA Industry Peers by Asset Resilience Ratio
Compare COSMO Pharmaceuticals SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for COSMO Pharmaceuticals SA (2009–2024)
The table below shows the annual Asset Resilience Ratio data for COSMO Pharmaceuticals SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.26% | £98.67 Million ≈ $132.50 Million |
£646.77 Million ≈ $868.56 Million |
+8.00pp |
| 2022-12-31 | 7.26% | £55.13 Million ≈ $74.03 Million |
£759.59 Million ≈ $1.02 Billion |
+4.32pp |
| 2021-12-31 | 2.94% | £23.65 Million ≈ $31.76 Million |
£805.56 Million ≈ $1.08 Billion |
-1.58pp |
| 2020-12-31 | 4.51% | £26.91 Million ≈ $36.14 Million |
£596.16 Million ≈ $800.59 Million |
-22.46pp |
| 2019-12-31 | 26.97% | £157.82 Million ≈ $211.94 Million |
£585.16 Million ≈ $785.82 Million |
+4.80pp |
| 2018-12-31 | 22.18% | £138.75 Million ≈ $186.32 Million |
£625.69 Million ≈ $840.24 Million |
+16.60pp |
| 2017-12-31 | 5.57% | £27.76 Million ≈ $37.28 Million |
£497.97 Million ≈ $668.73 Million |
-5.44pp |
| 2016-12-31 | 11.01% | £48.84 Million ≈ $65.58 Million |
£443.47 Million ≈ $595.55 Million |
+0.72pp |
| 2015-12-31 | 10.29% | £45.06 Million ≈ $60.52 Million |
£437.94 Million ≈ $588.12 Million |
-0.94pp |
| 2014-12-31 | 11.23% | £25.33 Million ≈ $34.01 Million |
£225.62 Million ≈ $302.99 Million |
-38.91pp |
| 2013-12-31 | 50.13% | £121.82 Million ≈ $163.60 Million |
£243.00 Million ≈ $326.33 Million |
+50.13pp |
| 2012-12-31 | 0.00% | £1.00 ≈ $1.34 |
£151.84 Million ≈ $203.91 Million |
-0.11pp |
| 2010-12-31 | 0.11% | £101.00K ≈ $135.63K |
£91.83 Million ≈ $123.31 Million |
-0.08pp |
| 2009-12-31 | 0.19% | £139.00K ≈ $186.66K |
£71.46 Million ≈ $95.97 Million |
-- |
About COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more